187 related articles for article (PubMed ID: 35053455)
1. ATX-101, a Peptide Targeting PCNA, Has Antitumor Efficacy Alone or in Combination with Radiotherapy in Murine Models of Human Glioblastoma.
Gravina GL; Colapietro A; Mancini A; Rossetti A; Martellucci S; Ventura L; Di Franco M; Marampon F; Mattei V; Biordi LA; Otterlei M; Festuccia C
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053455
[TBL] [Abstract][Full Text] [Related]
2. Targeting proliferating cell nuclear antigen and its protein interactions induces apoptosis in multiple myeloma cells.
Müller R; Misund K; Holien T; Bachke S; Gilljam KM; Våtsveen TK; Rø TB; Bellacchio E; Sundan A; Otterlei M
PLoS One; 2013; 8(7):e70430. PubMed ID: 23936203
[TBL] [Abstract][Full Text] [Related]
3. Increased Anticancer Efficacy of Intravesical Mitomycin C Therapy when Combined with a PCNA Targeting Peptide.
Gederaas OA; Søgaard CD; Viset T; Bachke S; Bruheim P; Arum CJ; Otterlei M
Transl Oncol; 2014 Dec; 7(6):812-23. PubMed ID: 25500092
[TBL] [Abstract][Full Text] [Related]
4. PCNA-interacting peptides reduce Akt phosphorylation and TLR-mediated cytokine secretion suggesting a role of PCNA in cellular signaling.
Olaisen C; Müller R; Nedal A; Otterlei M
Cell Signal; 2015 Jul; 27(7):1478-87. PubMed ID: 25797046
[TBL] [Abstract][Full Text] [Related]
5. PCNA regulates primary metabolism by scaffolding metabolic enzymes.
Røst LM; Ræder SB; Olaisen C; Søgaard CK; Sharma A; Bruheim P; Otterlei M
Oncogene; 2023 Feb; 42(8):613-624. PubMed ID: 36564470
[TBL] [Abstract][Full Text] [Related]
6. APIM-Mediated REV3L⁻PCNA Interaction Important for Error Free TLS Over UV-Induced DNA Lesions in Human Cells.
Ræder SB; Nepal A; Bjørås KØ; Seelinger M; Kolve RS; Nedal A; Müller R; Otterlei M
Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30597836
[TBL] [Abstract][Full Text] [Related]
7. The role of PCNA as a scaffold protein in cellular signaling is functionally conserved between yeast and humans.
Olaisen C; Kvitvang HFN; Lee S; Almaas E; Bruheim P; Drabløs F; Otterlei M
FEBS Open Bio; 2018 Jul; 8(7):1135-1145. PubMed ID: 29988559
[TBL] [Abstract][Full Text] [Related]
8. "Two hits - one stone"; increased efficacy of cisplatin-based therapies by targeting PCNA's role in both DNA repair and cellular signaling.
Søgaard CK; Blindheim A; Røst LM; Petrović V; Nepal A; Bachke S; Liabakk NB; Gederaas OA; Viset T; Arum CJ; Bruheim P; Otterlei M
Oncotarget; 2018 Aug; 9(65):32448-32465. PubMed ID: 30197755
[TBL] [Abstract][Full Text] [Related]
9. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
[TBL] [Abstract][Full Text] [Related]
10. Targeting Glioma Initiating Cells with A combined therapy of cannabinoids and temozolomide.
López-Valero I; Saiz-Ladera C; Torres S; Hernández-Tiedra S; García-Taboada E; Rodríguez-Fornés F; Barba M; Dávila D; Salvador-Tormo N; Guzmán M; Sepúlveda JM; Sánchez-Gómez P; Lorente M; Velasco G
Biochem Pharmacol; 2018 Nov; 157():266-274. PubMed ID: 30195736
[TBL] [Abstract][Full Text] [Related]
11. APIM-peptide targeting PCNA improves the efficacy of docetaxel treatment in the TRAMP mouse model of prostate cancer.
Søgaard CK; Moestue SA; Rye MB; Kim J; Nepal A; Liabakk NB; Bachke S; Bathen TF; Otterlei M; Hill DK
Oncotarget; 2018 Feb; 9(14):11752-11766. PubMed ID: 29545934
[TBL] [Abstract][Full Text] [Related]
12. Autotaxin Inhibition with PF-8380 Enhances the Radiosensitivity of Human and Murine Glioblastoma Cell Lines.
Bhave SR; Dadey DY; Karvas RM; Ferraro DJ; Kotipatruni RP; Jaboin JJ; Hallahan AN; Dewees TA; Linkous AG; Hallahan DE; Thotala D
Front Oncol; 2013; 3():236. PubMed ID: 24062988
[TBL] [Abstract][Full Text] [Related]
13. Identification of a novel, widespread, and functionally important PCNA-binding motif.
Gilljam KM; Feyzi E; Aas PA; Sousa MM; Müller R; Vågbø CB; Catterall TC; Liabakk NB; Slupphaug G; Drabløs F; Krokan HE; Otterlei M
J Cell Biol; 2009 Sep; 186(5):645-54. PubMed ID: 19736315
[TBL] [Abstract][Full Text] [Related]
14. ATX-101, a cell-penetrating protein targeting PCNA, can be safely administered as intravenous infusion in patients and shows clinical activity in a Phase 1 study.
Lemech CR; Kichenadasse G; Marschner JP; Alevizopoulos K; Otterlei M; Millward M
Oncogene; 2023 Feb; 42(7):541-544. PubMed ID: 36564469
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
[TBL] [Abstract][Full Text] [Related]
16. Nucleotide excision repair is associated with the replisome and its efficiency depends on a direct interaction between XPA and PCNA.
Gilljam KM; Müller R; Liabakk NB; Otterlei M
PLoS One; 2012; 7(11):e49199. PubMed ID: 23152873
[TBL] [Abstract][Full Text] [Related]
17. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
Koul D; Wang S; Wu S; Saito N; Zheng S; Gao F; Kaul I; Setoguchi M; Nakayama K; Koyama K; Shiose Y; Sulman EP; Hirota Y; Yung WKA
Oncotarget; 2017 Mar; 8(13):21741-21753. PubMed ID: 28423515
[TBL] [Abstract][Full Text] [Related]
18. Multiple Antitumor Molecular Mechanisms Are Activated by a Fully Synthetic and Stabilized Pharmaceutical Product Delivering the Active Compound Sulforaphane (SFX-01) in Preclinical Model of Human Glioblastoma.
Colapietro A; Rossetti A; Mancini A; Martellucci S; Ocone G; Pulcini F; Biordi L; Cristiano L; Mattei V; Delle Monache S; Marampon F; Gravina GL; Festuccia C
Pharmaceuticals (Basel); 2021 Oct; 14(11):. PubMed ID: 34832864
[TBL] [Abstract][Full Text] [Related]
19. On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.
Stechishin OD; Luchman HA; Ruan Y; Blough MD; Nguyen SA; Kelly JJ; Cairncross JG; Weiss S
Neuro Oncol; 2013 Feb; 15(2):198-207. PubMed ID: 23262510
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models.
Gravina GL; Mancini A; Mattei C; Vitale F; Marampon F; Colapietro A; Rossi G; Ventura L; Vetuschi A; Di Cesare E; Fox JA; Festuccia C
Oncotarget; 2017 May; 8(18):29865-29886. PubMed ID: 28415741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
